|
"許駿"的相關文件
顯示項目 11-35 / 148 (共6頁)
1 2 3 4 5 6 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2018-09-10T07:19:44Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Shen, Y.-C. and Hu, F.-C. and Jeng, Y.-M. and Chang, Y.-T. and Lin, Z.-Z. and Chang, M.-C. and Hsu, C. and Cheng, A.-L.; 沈盈君;胡賦強;鄭永銘;張毓廷;林宗哲;章明珠;許駿;鄭安理; SHEN, YING-CHUN;HU, FU-CHANG;JENG, YUNG-MING;CHANG, YU-TING;LIN, ZONG-ZHE;CHANG, MING-CHU;HSU, CHIUN;CHENG, ANN-LII; YUNG-MING JENG; YU-TING CHANG; ANN-LII CHENG; SHEN, YING-CHUN; HU, FU-CHANG; JENG, YUNG-MING; CHANG, YU-TING; LIN, ZONG-ZHE; CHANG, MING-CHU; HSU, CHIUN; CHENG, ANN-LII |
| 國家衛生研究院 |
2017 |
探討醛酮還原?1B10及其代謝產物參與肝細胞癌上皮細胞間質轉化及抗藥性之角色
|
劉俊揚;許駿;柯博升;郭呈欽;鄭靜枝;詹以吉 |
| 國立臺灣大學 |
2016 |
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression
|
Hsu, Chiun; Lin, Liang-In; Cheng, Yu-Che; Feng, Zi-Rui; Shao, Yu-Yun; Cheng, Ann-Lii; Ou, Da-Liang; 邵幼雲; 林亮音; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2016 |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang, Shih-Hung; Kuo, Ting-Chun; Wu, Hsu; Guo, Jhe-Cyuan; Hsu, Chiun; Hsu, Chih-Hung; Tien, Yu-Wen; Yeh, Kun-Huei; Cheng, Ann-Lii; Kuo, Sung-Hsin; 郭頌鑫; 鄭安理; 徐志宏; 許駿; 葉坤輝; 郭哲銓; 田郁文; 郭庭均; 楊士弘 |
| 國立臺灣大學 |
2016 |
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer
|
Chiang, Nai-Jung; Hsu, Chiun; Chen, Jen-Shi; Tsou, Hsiao-Hui; Shen, Ying-Ying; Chao, Yee; Chen, Ming-Huang; Yeh, Ta-Sen; Shan, Yan-Shen; Huang, Shiu-Feng; Chen, Li-Tzong; 許駿 |
| 國立臺灣大學 |
2016 |
Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy
|
Chen, Bang-Bin; Hsu, Chao-Yu; Yu, Chih-Wei; Liang, Po-Chin; Hsu, Chiun; Hsu, Chih-Hung; Cheng, Ann-Lii; Shih, Tiffany Ting-Fang; 許昭禹; 鄭安理; 陳邦斌; 徐志宏; 許駿; 梁博欽; 游治維 |
| 國立臺灣大學 |
2016 |
Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges
|
Lu, Li-Chun; Hsu, Chih-Hung; Hsu, Chiun; Cheng, Ann-Lii; 鄭安理; 徐志宏; 許駿; 呂理駿 |
| 國立臺灣大學 |
2016 |
Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study
|
Melero, I.; Sangro, B.; Yau, T.; Hsu, C.; Kudo, M.; Crocenzi, T.; Kim, T-Y.; Choo, S-P.; Trojan, J.; Meyer, T.; Welling, T. H., III; Yeo, W.; Chopra, A.; Anderson, J.; Dela Cruz, C.; Lang, L.; Neely, J.; El-Khoueiry, A.; 許駿 |
| 國立臺灣大學 |
2016 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
Shao, Y-Y.; Chen, B-B.; Lin, Z-Z.; Hsu, C-H.; Wang, M-J.; Cheng, A-L.; Hsu, C.; 邵幼雲; 林宗哲; 鄭安理; 陳邦斌; 徐志宏; 許駿 |
| 國家衛生研究院 |
2016 |
肝細胞癌中ZNF479所調控之第一型金屬硫蛋白作為抗藥性標的物及抗癌藥物篩選平台之探討與應用
|
劉俊揚;詹以吉;鄭靜枝;許駿;柯博升 |
| 國立臺灣大學 |
2015 |
Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
Ou, Da-Liang; Shyue, Song-Kun; Lin, Liang-In; Feng, Zi-Rui; Liou, Jun-Yang; Fan, Hsiang-Hsuan; Lee, Bin-Shyun; Hsu, Chiun; Cheng, Ann-Lii; 林亮音; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2015 |
LONG-TERM OUTCOME OF CHEMOTHERAPY-INDUCED HBV REACTIVATION IN LYMPHOMA PATIENTS WITH RESOLVED HBV INFECTION
|
Yang, H. -C.; Tsou, H. -H.; Chuang, M. -H.; Chen, C. -L.; Liu, T. -W.; Chen, P. -J.; Cheng, A. -L.; Hsu, C.; 鄭安理; 許駿; 陳培哲; 陳祈玲 |
| 國立臺灣大學 |
2015 |
The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia
|
Kuo, Hung-Yang; Lin, Zhong-Zhe; Kuo, Raymond; Shau, Wen-Yi; Lai, Chiu-Lin; Yang, Yen-Yun; Shao, Yu-Yun; Hsu, Chiun; Cheng, Wen-Fan; Cheng, Ann-Lii; Yang, James Chih-Hsin; Lai, Mei-Shu; 郭漢岳; 郭弘揚; 鄭文芳; 楊志新; 邵幼雲; 賴美淑; 林宗哲; 鄭安理; 許駿 |
| 國立臺灣大學 |
2015 |
Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)
|
Hsu, Chiun; Chen, Bang-Bin; Chen, Chien-Hung; Ho, Ming-Chih; Cheng, Jason Chia-Hsien; Kokudo, Norihiro; Murakami, Takamichi; Yeo, Winnie; Seong, Jinsil; Jia, Ji-Dong; Han, Kwan-Hyub; Cheng, Ann-Lii; 鄭安理; 成佳憲; 陳邦斌; 許駿; 陳健弘; 何明志 |
| 國家衛生研究院 |
2015 |
探討第一型金屬硫蛋白異構體在肝細胞癌中之選擇性調控及其可能之治療應用
|
劉俊揚;許駿;柯博升;詹以吉 |
| 國立臺灣大學 |
2014 |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity
|
Kuo, S-H; Yeh, K-H; Chen, L-T; Lin, C-W; Hsu, P-N; Hsu, C.; Wu, M-S; Tzeng, Y-S; Tsai, H-J; Wang, H-P; Cheng, A-L; 林中梧; 郭頌鑫; 鄭安理; 許駿; 葉坤輝; 王秀伯; 吳明賢; 許秉寧 |
| 國立臺灣大學 |
2014 |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou, Da-Liang; Chang, Chun-Jung; Jeng, Yung-Ming; Lin, Yi-Jang; Lin, Zhong-Zhe; Gandhi, Anita K.; Liao, Sheng-Chieh; Huang, Zi-Ming; Hsu, Chiun; Cheng, Ann-Lii; 鄭永銘; 張純榮; 林宗哲; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2014 |
Vertical blockade of the IGFR-PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin
|
Ou, Da-Liang; Lee, Bin-Shyun; Lin, Liang-In; Liou, Jun-Yang; Liao, Sheng-Chieh; Hsu, Chiun; Cheng, Ann-Lii; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2014 |
Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer
|
Shen, Ying-Chun; Li, Chung-Pin; Yen, Chia-Jui; Hsu, Chiun; Lin, Yu-Lin; Lin, Zhong-Zhe; Chen, Li-Tzong; Su, Wu-Chou; Chao, Yee; Yeh, Kun-Huei; Cheng, Ann-Lii; 林宗哲; 林育麟; 鄭安理; 許駿; 葉坤輝 |
| 國立臺灣大學 |
2014 |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao, Hsiang-Fong; Chen, I-Chun; Hsu, Chiun; Chang, Sin-Yuan; Chien, Shu-Fen; Chen, Yee-Chun; Hu, Fu-Chang; Yang, James Chih-Hsin; Cheng, Ann-Lii; Yeh, Kun-Huei; 楊志新; 高祥豐; 陳怡君; 鄭安理; 許駿; 葉坤輝; 陳宜君 |
| 國立臺灣大學 |
2014 |
The impact of diabetes mellitus on early cervical cancer in Asia: A population-based cohort study
|
Kuo, Hung-Yang; Lin, Zhong-Zhe; Kuo, Raymond Nienchen; Shau, Wen-Yi; Lai, Chiu-Lin; Yang, Yen-Yun; Shao, Yu Yun; Hsu, Chiun; Chang, Wen-Fang; Chang, Ann-Lii; Yang, James Chih-Hsin; Lai, Mei-Shu; 楊志新; 邵幼雲; 賴美淑; 鄭安理; 許駿; 賴秋伶 |
| 國立臺灣大學 |
2014 |
Comparison of Characteristics and Transarterial Chemoembolization Outcomes in Patients with Unresectable Hepatocellular Carcinoma and Different Viral Etiologies
|
Chen, Bang-Bin; Shih, I-Lun; Wu, Chih-Horng; Hsu, Chiun; Chen, Chien-Hung; Shih, Tiffany Ting-Fang; Liu, Kao-Lang; Liang, Po-Chin; 吳志宏; 施庭芳; 陳邦斌; 許駿; 施怡倫; 陳健弘; 劉高郎; 梁博欽 |
| 國立臺灣大學 |
2014 |
Chemotherapy-Induced Hepatitis B Reactivation in Lymphoma Patients With Resolved HBV Infection: A Prospective Study
|
Hsu, Chiun; Tsou, Hsiao-Hui; Lin, Shyh-Jer; Wang, Ming-Chung; Yao, Ming; Hwang, Wen-Li; Kao, Woei-Yau; Chiu, Chang-Fang; Lin, Sheng-Fung; Lin, Johnson; Chang, Cheng-Shyong; Tien, Hwei-Fang; Liu, Tsang-Wu; Chen, Pei-Jer; Cheng, Ann-Lii; 姚明; 鄭安理; 許駿; 田蕙芬; 陳培哲 |
| 國立臺灣大學 |
2014 |
H3K9 Histone Methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 Pathway to Suppress Lung Cancer Metastasis
|
Wu, Pei-Chun; Lu, Jeng-Wei; Yang, Jer-Yen; Lin, I-Hsuan; Ou, Da-Liang; Lin, Yu-Hsiang; Chou, Kuan-Hsien; Huang, Wen-Feng; Wang, Wan-Ping; Huang, Yih-Leh; Hsu, Chiun; Lin, Liang-In; Lin, Yueh-Min; Shen, C. -K. James; Tzeng, Tsai-Yu; 林亮音; 許駿; 歐大諒 |
| 國立臺灣大學 |
2014 |
Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan
|
Chang, Yu-Ting; Chang, Ming-Chu; Huang, Kai-Wen; Tung, Chien-Chih; Hsu, Chiun; Wong, Jau-Min; 董建志; 黃凱文; 許駿; 章明珠; 張毓廷 |
顯示項目 11-35 / 148 (共6頁)
1 2 3 4 5 6 > >>
每頁顯示[10|25|50]項目
|
